# Effect of AKB-6548 on the Pharmacokinetics of Celecoxib

> **NCT02502500** · PHASE1 · COMPLETED · sponsor: **Akebia Therapeutics** · enrollment: 12 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** AKB-6548

## Key facts

- **NCT ID:** NCT02502500
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2015-07
- **Final completion:** 2015-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02502500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02502500, "Effect of AKB-6548 on the Pharmacokinetics of Celecoxib". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02502500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*